MEI Pharma, a publicly traded pharmaceutical company, closed a $100 million private placement to turn itself into a litecoin ...

A little-known Nasdaq-listed drugmaker plans to invest $100M in litecoin, appoints Charlie Lee to its board and names GSR as ...

Key Highlights. Adoption of Litecoin Treasury Strategy - Initial purchase of 4,982 LTC as part of a new treasury allocation, positioning Luxxfolio for the next wave of crypto payment adoption.; ...

MEI Pharma announces a $100 million private placement to adopt Litecoin as its primary treasury reserve asset.

Charlie Lee and GSR acted as lead investors, alongside participation from the Litecoin Foundation and prominent crypto venture capital firms and infrastructure providers, including Mozayyx, Parafi, ...

MEI Pharma raises $100 million to buy Litecoin, boosting stock value and signaling confidence in LTC's future growth.

MEI Pharma ( (MEIP)) has issued an update. On July 17, 2025, MEI Pharma entered into securities purchase agreements for a private placement offering, raising approximately $100 million to initiate a ...

MEI Pharma (NASDAQ:MEIP) has launched a $100 million Litecoin (CRYPTO: LTC) treasury program, backed by Titan Partners Group ...

MEI Pharma unveils bold $100M Litecoin treasury plan with Titan, GSR, Litecoin Foundation, expanding altcoin adoption beyond ...

MEI Pharma commits $100M to Litecoin with Charlie Lee joining its board, signaling major institutional interest in LTC.

Litecoin price prediction chatter has returned with force after LTC surged 23% in a single day, hitting $119, its highest ...